Innoviva Inc.
951 Gateway Boulevard
South San Francisco
California
94080
United States
Tel: 650-808-6000
Website: http://www.thrxinc.com/
440 articles with Innoviva Inc.
-
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
3/13/2023
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR).
-
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
2/28/2023
Innoviva, Inc. today reported financial results for the fourth quarter ended December 31, 2022.
-
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
11/30/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the new drug application (NDA) for SUL-DUR, an investigational drug for the treatment of infections caused by Acinetobacter baumannii-calcoaceticus complex (ABC), including multi-drug resistant and carbapenem-resistant strains.
-
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
11/9/2022
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2022.
-
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
10/14/2022
La Jolla Pharmaceutical Company today announced that five abstracts highlighting XERAVA (eravacycline) have been selected for poster presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
-
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022Six abstracts selected for presentation, including three oral presentations
10/12/2022
Entasis Therapeutics Holdings Inc. announced that six abstracts highlighting sulbactam-durlobactam have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
-
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
9/8/2022
Innoviva, Inc. announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14th at 11:10 a.m. Eastern Time.
-
Innoviva Completes Acquisition of La Jolla Pharmaceutical
8/22/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”).
-
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
7/27/2022
Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”), a diversified holding company with a portfolio of royalties and a growing portfolio of healthcare assets in infectious disease and other areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022.
-
Under the terms of the deal, Theravance and Innoviva are surrendering 85% and 15% of their stakes in Trelegy in exchange for $1.1 billion and $282 million from Royalty, respectively.
-
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
7/13/2022
Innoviva, Inc. announced that the company has entered into an agreement to sell its 15% economic stake in Theravance Respiratory Company LLC, which receives royalties stemming from sales of TRELEGY® ELLIPTA®, to Royalty Pharma plc for an upfront cash payment of approximately $282 million and a potential $50 million contingent sales-based milestone payment.
-
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
-
Innoviva to Acquire La Jolla Pharmaceutical Company
7/11/2022
Innoviva, Inc. and La Jolla Pharmaceutical Company announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
-
Innoviva Completes Acquisition of Entasis Therapeutics
7/11/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc.
-
Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
7/8/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc.
-
Burlingame, CA-based Innoviva is buying all of Waltham, MA-based Entasis Therapeutics' available shares at $2.20 per share. Currently, Innoviva owns about 60% of Entasis’ outstanding shares.
-
Innoviva to Acquire Entasis Therapeutics
5/23/2022
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”), today announced the companies have entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis not already owned by Innoviva at a price of $2.20 per share in cash.
-
Innoviva Reports First Quarter 2022 Financial Results
4/27/2022
Innoviva, Inc. reported financial results for the first quarter ended March 31, 2022.
-
Innoviva, Inc. Prices Upsized Offering of $225 Million of 2.125% Convertible Senior Notes
3/3/2022
Innoviva, Inc. (NASDAQ: INVA) (the “Company” or “Innoviva”) today announced the pricing of $225 million aggregate principal amount of the Company’s 2.125% convertible senior notes due 2028 (the “Notes”).
-
Innoviva Reports Fourth Quarter 2021 Financial Results
2/9/2022
Innoviva, Inc. reported financial results for the fourth quarter and the year ended December 31, 2021.